Clinical trials: Aspergillus Infection
Acquired Immunodeficiency Syndrome, Aspergillosis
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
Invasive aspergillosis is a fungal disease which is increasing in incidence with the increase in immunocompromised persons in our population.
- Conditions
- Acquired Immunodeficiency Syndrome, Aspergillosis, HIV Infections, Immunologic Deficiency Syndromes
- Trial name
- NCT00001646
- Testing
- Voriconazole, Amphotericin B
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia
Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia
The trial evaluates the overall tolerability of the drug and the efficacy of aerosolised amphotericin B as a lipid complex (ABLC) for primary prophylaxis of invasive pulmonary aspergillosis (IPA) in pediatric patients with acute…
- Conditions
- Invasive Pulmonary Aspergillosis, Lymphoblastic Leukaemia, Myeloblastic Leukaemia, Lymphoblastic Leukemia
- Trial name
- NCT01615809
- Testing
- AMPHOTERICIN B
- Where
- Spain
- Volunteers
- 32 people
- Sponsor
- Fundació Sant Joan de Déu
Invasive Aspergillosis
A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children
The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.
- Trial name
- NCT00836875
- Testing
- Voriconazole
- Where
- 25 sites in United States, Canada and 6 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Infection, Pulmonary Complications
Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis
RATIONALE: Antifungal therapy with voriconazole or amphotericin B may be an effective treatment for aspergillosis. It is not yet known whether voriconazole is more effective than amphotericin B in treating patients with…
- Trial name
- NCT00003031
- Testing
- amphotericin B deoxycholate, voriconazole
- Where
- 74 sites in United States, Australia and 13 more
- Volunteers
- 212 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Allergic Bronchopulmonary Aspergillosis
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to antigens released by the fungus Aspergillus fumigatus.
- Trial name
- NCT00974766
- Testing
- Glucocorticoids
- Where
- India
- Volunteers
- 92 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Invasive Aspergillosis, Other Fungal Infections
Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment
To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by…
- Trial name
- NCT00158730
- Testing
- AmBisome
- Volunteers
- 800 people
- Sponsor
- Gilead Sciences
Aspergillosis
THYME AND CARVACROLL Nanoparticle Effect on Fungi
Invasive Aspergillosis (IA) has increasingly been recognized as an emerging disease of non-neutropenic patients and in patients admitted to the ICU, even in the absence of an apparent predisposing immune-deficiency, with…
- Trial name
- NCT04431804
- Testing
- silver nanoparticle
- Where
- Egypt
- Volunteers
- 210 people
- Sponsor
- Assiut University
Infection, Unspecified Adult Solid Tumor, Protocol Specific
Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections
RATIONALE: Antifungals such as voriconazole may be effective in controlling fungal infections. Combining voriconazole with interferon gamma may be more effective than voriconazole alone in treating fungal infections.
- Trial name
- NCT00059878
- Testing
- recombinant interferon gamma, voriconazole
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cerebral Aspergillosis, Invasive Aspergillosis
European Study of Cerebral Aspergillosis Treated With Isavuconazole
Study clinical context Cerebral aspergillosis (CA) is a rare location of invasive aspergillosis (IA), associated with a high morbidity and mortality.
- Trial name
- ESCAI (NCT04486885)
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Imagine Institute
Invasive Aspergillosis
Diagnosing Invasive Aspergillosis by Polymerase Chain Reaction (PCR) Based Investigation of Bronchoalveolar Lavage Samples During Antifungal Therapy
Invasive pulmonary aspergillosis (IPA) remains a major cause for morbidity and mortality in patients (pts) with hematologic malignancies.
- Trial name
- NCT01448226
- Where
- 22 sites in Austria, Germany
- Volunteers
- 221 people
- Sponsor
- Heidelberg University
Mycoses
Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A.
- Trial name
- NCT00034632
- Testing
- Posaconazole oral suspension
- Sponsor
- Merck Sharp & Dohme LLC
Mycoses
Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041)
This study is designed to evaluate the safety, tolerance and efficacy of Posaconazole (SCH 56592) under an open label, treatment protocol for subjects with invasive fungal infections: A: which are refractory or resistant to…
- Trial name
- NCT00034658
- Testing
- Posaconazole
- Volunteers
- 336 people
- Sponsor
- Merck Sharp & Dohme LLC
Invasive Aspergillosis
Diagnosing Pulmonary Aspergillosis in Patients With Hematological Malignancies: A Multicentre Prospective Evaluation of an Aspergillus PCR Assay and a Galactomannan ELISA in Bronchoalveolar Lavage Samples
Diagnosing invasive pulmonary aspergillosis (IPA) remains a challenge in patients (pts) with hematological malignancies. The clinical significance of testing bronchoalveolar lavage (BAL) samples both with polymerase chain…
- Trial name
- NCT01430663
- Where
- 9 sites in Austria, Germany
- Volunteers
- 87 people
- Sponsor
- Heidelberg University
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis, Aspergillus Infections
ATCF (Azole Therapy in Cystic Fibrosis)
Aspergillus infection is an infectious complication which frequently occurs in cystic fibrosis. The efficacy of azole therapy in patients with cystic fibrosis with persistent positive sputums for Aspergillus is still unknown.
- Trial name
- ATCF (NCT01576315)
- Testing
- Itraconazole/voriconazole
- Where
- 15 sites in France, United Kingdom
- Volunteers
- 11 people
- Sponsor
- Rennes University Hospital
Cystic Fibrosis, Aspergillosis
A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection
This study will provide: (1) new insights in the prevalence of Aspergillus infection in children and adolescents with CF aged 8-17 yrs; (2) an in silico modelled dose of posaconazole for children and adolescents with CF and…
- Trial name
- cASPerCF (NCT04966234)
- Testing
- Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML
- Where
- 31 sites in Czechia, France and 9 more
- Volunteers
- 135 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Bronchiectasis, Bronchiectasis Adult
Compare Oral Itraconazole and Standard Care Versus Standard Care Alone in Patients With Non-cystic Fibrosis Related Bronchiectasis With Chronic Aspergillus Infection in Reducing Bronchiectasis Exacerbations
There is an intricate link between bronchiectasis and fungi. Patients with cystic fibrosis frequently manifest fungal sensitization and fungal colonization with Aspergillus fumigatus.6 Aspergillus species also has a…
- Trial name
- BAIT (NCT06160713)
- Testing
- Itraconazole 65 MG, Standard care
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diphtheria, Acellular Pertussis
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.
This study is being conducted to assess impact of maternal immunisation against pertussis in infants ≤12 months of age before and after introduction of pertussis maternal immunisation in Bogota, Colombia from January…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus, Aspergillosis, Allergic Bronchopulmonary
- Trial name
- NCT02569879
- Testing
- Pertussis maternal immunization
- Where
- Colombia
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Invasive Pulmonary Aspergillosis, Invasive Fungal Disease
LFD of Aspergillus Antigen in Paediatrics
Many children and young people are at risk of invasive fungal disease (IFD), such as those who have had a haematopoietic stem cell transplants, those with an immune deficiency or those who are prescribed immunosuppressive drugs…
- Trial name
- LFD-AsPaeds (NCT05569824)
- Testing
- Lateral-flow Device
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St George's University Hospitals NHS Foundation Trust